Financial Performance - The company's revenue for Q3 2021 was ¥279,336,611.18, representing a year-over-year increase of 17.57%[5] - The net profit attributable to shareholders decreased by 21.85% to ¥25,445,617.33 compared to the same period last year[5] - The net profit excluding non-recurring gains and losses increased by 191.79% to ¥24,724,995.47 for the current period[6] - Basic and diluted earnings per share were both ¥0.06, down 25.00% from the previous year[6] - Total operating revenue for the first three quarters of 2021 reached CNY 910,541,434.13, an increase of 11.97% compared to CNY 813,140,630.47 in the same period of 2020[18] - Net profit for the first three quarters of 2021 was CNY 76,080,576.63, slightly up from CNY 75,074,690.02 in the same period of 2020[19] - Basic and diluted earnings per share for the first three quarters of 2021 were both CNY 0.19, compared to CNY 0.20 in the same period of 2020[20] - The total comprehensive income for the first three quarters of 2021 was CNY 76,080,576.63, slightly higher than CNY 75,074,690.02 in the same period of 2020[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,478,428,894.37, a decrease of 2.81% from the end of the previous year[6] - Total current assets as of September 30, 2021, amount to ¥810,081,054.26, a decrease from ¥959,636,994.38 at the end of 2020[15] - Total liabilities decreased to ¥540,986,828.66 from ¥604,682,089.37 year-over-year[16] - Non-current assets increased to ¥668,347,840.11 from ¥561,522,896.87 year-over-year[15] - The company reported a decrease in total liabilities and equity to CNY 1,478,428,894.37 from CNY 1,521,159,891.25[19] - The total liabilities increased to ¥604,682,089.37 in Q3 2021 from ¥613,546,448.94 at the beginning of the year, reflecting a rise in financial obligations[26] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥24,700,295.50 for the year-to-date period[6] - Cash flow from operating activities showed a net outflow of CNY 24,700,295.50, an improvement from a net outflow of CNY 175,087,499.26 in the same period of 2020[22] - Cash inflow from operating activities totaled CNY 885,484,138.31, compared to CNY 673,577,454.69 in the previous year, indicating a growth of 31.39%[22] - The net cash flow from investing activities for Q3 2021 was -¥103,070,551.24, compared to -¥55,124,248.50 in Q3 2020, indicating a significant increase in cash outflow[23] - The total cash inflow from financing activities in Q3 2021 was ¥331,483,500.00, down from ¥438,717,620.92 in Q3 2020, reflecting a decrease of approximately 24.4%[23] - The net cash flow from financing activities for Q3 2021 was ¥14,803,011.93, a decrease of 94.9% compared to ¥290,281,790.38 in Q3 2020[23] - The cash and cash equivalents at the end of Q3 2021 stood at ¥227,909,609.21, a decrease from ¥340,877,444.02 at the beginning of the period[23] - The company reported a cash outflow of ¥112,967,834.81 for the net increase in cash and cash equivalents in Q3 2021, contrasting with an inflow of ¥60,070,042.62 in Q3 2020[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,798[12] - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 167,079,000 shares, accounting for 41.7% of total shares[12] - The company reported a total equity attributable to shareholders of ¥933,822,081.04, reflecting a 1.89% increase from the previous year[6] - The company's total equity remained stable at ¥916,477,801.88, indicating no significant changes in shareholder equity during the period[27] Research and Development - Research and development expenses increased by 74.96% year-to-date, indicating a focus on drug development[10] - Research and development expenses increased significantly to CNY 55,627,356.28, compared to CNY 31,794,530.18 in the previous year, reflecting a growth of 74.93%[18] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[14] - The company executed a new leasing standard starting January 1, 2021, which resulted in adjustments to the financial statements[27] - The company recorded an investment loss of CNY 1,820,626.10, contrasting with an investment gain of CNY 950,500.89 in the previous year[18] - The weighted average return on equity decreased by 1.41 percentage points to 2.70%[6] - Cash and cash equivalents decreased to ¥227,909,609.21 from ¥345,877,444.02 year-over-year[14] - Inventory as of September 30, 2021, is ¥191,501,962.40, up from ¥185,990,670.02 year-over-year[15] - Short-term borrowings increased to ¥256,326,100.42 from ¥210,278,118.94 year-over-year[16]

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥631.20 million, representing a 9.67% increase compared to ¥575.55 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥51.91 million, an increase of 22.11% from ¥42.51 million in the previous year[19]. - The basic earnings per share for the first half of 2021 was ¥0.13, up 8.33% from ¥0.12 in the same period last year[19]. - The net cash flow from operating activities improved significantly to approximately ¥22.57 million, compared to a negative cash flow of ¥153.68 million in the previous year[19]. - The total assets at the end of the reporting period were approximately ¥1.40 billion, a decrease of 7.81% from ¥1.52 billion at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥908.38 million, down 0.88% from ¥916.48 million at the end of the previous year[19]. - The operating cost increased by 26.65% to ¥273,649,973.74 from ¥216,072,664.31 year-on-year[42]. - Research and development expenses surged by 94.84% to ¥40,810,478.42, primarily due to increased investment in drug development[43]. Cash Flow and Investments - The company indicated that the increase in cash flow from operating activities was primarily due to improved accounts receivable collection and the maturity of bank acceptance bills[20]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[6]. - The company is actively investing in new projects, including the "Huluwa Group Meian Children's Medicine Intelligent Manufacturing Base" and "Guangxi Weiwei Phase II Production Base" projects[44]. - The company plans to raise funds through a private placement to invest in the "Guangxi Weiwei Phase II Production Base Project" and "Huliwa Group Meian Children's Medicine Intelligent Manufacturing Base Project"[51]. Market Position and Product Development - The pediatric pharmaceutical market is expected to grow due to the implementation of the three-child policy and rising quality demands for children's medication[28]. - The company focuses on the development and production of pediatric medications, including respiratory, digestive, and anti-infection drugs[30]. - The company is positioned as a leader in the treatment of pediatric respiratory diseases in China[30]. - The company has established a pediatric drug R&D academician workstation and has been recognized as a high-tech enterprise since 2010[30]. - The company emphasizes the development of new products, including sugar-free and ultra-concentrated gastrointestinal medications, to address both adult and pediatric needs[36]. Research and Development - The company has increased its R&D investment annually, collaborating with top research institutions to enhance its capabilities in pediatric and traditional Chinese medicine[34]. - The company has established multiple research centers and partnerships to enhance its R&D capabilities in pediatric medications[34]. - The company is committed to accelerating the construction progress of fundraising investment projects to quickly realize the expected benefits and enhance shareholder returns[155]. Environmental Compliance - The company reported no exceedances in wastewater discharge, adhering to national pollution discharge standards[70]. - The company’s total CODCr emissions for the first year are projected at 2.289 tons, with no exceedances reported in subsequent years[71]. - The company’s nitrogen oxides emissions from the boiler are compliant with the standard of 150 mg/L, with no exceedances noted[71]. - The company has implemented safety management protocols to prevent accidents, but risks remain from equipment failures or natural disasters that could disrupt operations[60]. - The company has established a comprehensive monitoring system for emissions, ensuring real-time compliance with environmental regulations[82]. Shareholder Commitments and Governance - The company has committed to not transferring or managing shares held prior to the IPO for 36 months from the listing date[126]. - If the stock price falls below the issue price for 20 consecutive trading days within six months post-IPO, the lock-up period will automatically extend by six months[126]. - The company will publicly disclose any failure to fulfill commitments and will compensate investors for any resulting losses[166]. - The controlling shareholder and actual controller commit not to interfere with the company's management activities or infringe on its interests, ensuring compliance with relevant regulations[157]. Legal Matters - The company is involved in a significant lawsuit regarding a technical service contract dispute, seeking a total of RMB 3.74 million (approximately USD 0.57 million) in compensation[172]. - The lawsuit involves a claim against Hainan Xinlai Pharmaceutical Technology Co., Ltd. for the return of RMB 1 million (approximately USD 0.15 million) and additional economic losses of RMB 2.74 million (approximately USD 0.41 million)[172]. - The company has committed to minimizing investor losses and protecting their interests in light of the ongoing legal issues[172]. Financial Guarantees and Liabilities - The total guarantee amount (including guarantees to subsidiaries) is 123,408,800.00, which accounts for 13.59% of the company's net assets[181]. - The amount of guarantees provided to subsidiaries during the reporting period is 82,000,000.00, with a total balance of 123,408,800.00 at the end of the reporting period[181]. - The company has outstanding loans totaling 3,500.00 million, with specific amounts yet to be repaid as of June 30, 2021[183]. - The company has entered into multiple loan agreements with various banks, with amounts ranging from 1,000.00 to 10,000.00, with specific repayment terms[183].

Financial Performance - Operating revenue for the quarter was CNY 308,485,460.64, representing a 19.23% increase year-over-year[6] - Net profit attributable to shareholders was CNY 23,699,852.49, up 39.45% compared to the same period last year[6] - Basic earnings per share increased to CNY 0.06, reflecting a 20% growth from CNY 0.05 in the same quarter last year[7] - The company reported a total profit of CNY 28,828,284.45 for Q1 2021, an increase of 31.4% from CNY 21,934,476.72 in Q1 2020[25] - Net profit for Q1 2021 reached CNY 23,683,806.11, representing a 39.5% increase from CNY 16,994,854.81 in Q1 2020[25] - The company’s total comprehensive income for Q1 2021 was CNY 23,683,806.11, compared to CNY 16,994,854.81 in Q1 2020[26] Cash Flow - The net cash flow from operating activities improved to -CNY 77,986,423.25, a 15.61% increase from -CNY 92,414,561.50 in the previous year[6] - In Q1 2021, the cash inflow from operating activities totaled ¥265,282,305.31, an increase from ¥236,968,976.77 in Q1 2020, representing an increase of approximately 12.5%[32] - The net cash outflow from operating activities was ¥77,986,423.25 in Q1 2021, an improvement compared to a net outflow of ¥92,414,561.50 in Q1 2020, indicating a reduction of about 15.6%[32] - The cash inflow from investment activities was ¥20,244,535.72 in Q1 2021, significantly lower than ¥140,492,901.51 in Q1 2020, reflecting a decrease of approximately 85.6%[33] - The net cash outflow from investment activities was ¥42,071,436.45 in Q1 2021, compared to a net outflow of ¥76,125,340.05 in Q1 2020, showing an improvement of about 44.8%[33] - The cash inflow from financing activities reached ¥165,983,500.00 in Q1 2021, up from ¥90,000,000.00 in Q1 2020, marking an increase of approximately 84.4%[33] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,525,004,570, a 0.25% increase from the previous year[6] - The company's total current assets as of March 31, 2021, amounted to RMB 276,514,702.79, a decrease from RMB 345,877,444.02 as of December 31, 2020[17] - Total current assets amounted to $933.16 million, a decrease from $959.64 million in the previous period, reflecting a decline of approximately 2.6%[18] - Total non-current assets increased to $591.84 million from $561.52 million, representing an increase of about 5.4%[18] - Total liabilities decreased to $579.94 million from $604.68 million, a reduction of approximately 4.1%[19] - Long-term borrowings increased to $110.65 million from $52.05 million, representing a substantial increase of approximately 112.5%[19] Shareholder Information - The total number of shareholders reached 33,337 at the end of the reporting period[10] - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 41.76% of the shares, totaling 167,079,000 shares[11] Research and Development - Research and development expenses rose by 46.51% to RMB 13,690,147.15, indicating increased investment in drug development[14] - Research and development expenses increased to CNY 13,690,147.15 in Q1 2021, up 46.5% from CNY 9,344,219.90 in Q1 2020[24] Other Financial Metrics - The company reported a weighted average return on net assets of 2.55%, a decrease of 0.05 percentage points from the previous year[7] - The company received government subsidies amounting to RMB 4,118,315.28, a 215.09% increase compared to the previous year[15] - Unappropriated profits rose to $266.77 million from $244.52 million, an increase of about 9.1%[23] - The company experienced a credit impairment loss of CNY -2,440,548.31 in Q1 2021, compared to a loss of CNY -2,471,185.11 in Q1 2020[25] - Other income for Q1 2021 was CNY 4,118,315.28, significantly higher than CNY 1,307,040.45 in Q1 2020[24]

Financial Performance - The company's net profit attributable to shareholders for 2020 was CNY 121,502,482.07, a slight increase of 0.97% compared to CNY 120,329,315.60 in 2019[20]. - Total operating revenue for 2020 was CNY 1,161,705,769.57, representing a decrease of 11.04% from CNY 1,305,918,058.70 in 2019[20]. - The net profit attributable to shareholders was CNY 121.50 million, an increase of 0.97% year-on-year, while the net profit excluding non-recurring gains and losses decreased by 9.96% to CNY 81.33 million[46]. - The gross profit margin for the pharmaceutical manufacturing sector was 61.81%, down 0.15 percentage points from the previous year[51]. - The company achieved operating revenue of CNY 1,161.71 million, a decrease of 11.04% compared to the previous year[46]. Assets and Liabilities - The company's total assets as of December 31, 2020, reached CNY 1,521,159,891.25, an increase of 39.99% compared to CNY 1,086,606,324.64 at the end of 2019[21]. - The net assets attributable to shareholders increased by 42.32% to CNY 916,477,801.88 from CNY 643,935,667.58 in 2019[21]. - Accounts receivable increased by CNY 122.15 million, representing an 82.47% increase, primarily due to an increase in receivables within the credit period[35]. - The company reported a significant increase in short-term borrowings, which reached ¥210,278,118.94, representing 13.82% of total liabilities, up 131.52% from the previous period[66]. Cash Flow - Cash flow from operating activities showed a significant decline, with a net cash inflow of CNY 3,299,892.58, down 97.72% from CNY 144,512,810.40 in 2019[21]. - Cash flow from investing activities was negative at CNY -77,615,525.33, worsening by 40.27% compared to CNY -55,331,633.10 in 2019[21]. - Cash flow from financing activities improved significantly, with a net inflow of CNY 261,103,775.99, compared to a net outflow of CNY -113,493,382.08 in 2019, marking a 330.06% increase[21]. - The company reported a significant decrease in cash flow from operating activities, with a net cash flow of CNY 3.30 million, down 97.72% year-on-year[48]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of CNY 1.5 per 10 shares, totaling CNY 60,016,312.80, which accounts for 49.40% of the net profit attributable to shareholders for 2020[5]. - In 2019, the company distributed a cash dividend of RMB 2.25 per 10 shares, amounting to RMB 81,001,969.20, which was 67.32% of the net profit attributable to shareholders[117]. - The company emphasizes a proactive profit distribution policy, considering profitability and funding needs, and submits profit distribution plans for shareholder approval[115]. Research and Development - The company has increased its R&D investment, focusing on pediatric, digestive, respiratory, and anti-infection treatments, while also developing classic traditional Chinese medicine formulas[42]. - The company’s R&D investment amounted to 11,825.18 million RMB, representing 4.80% of its operating revenue and 6.08% of its net assets[93]. - The company is focusing on innovation in drug development, with a commitment to increasing R&D investment in response to national policies encouraging innovation[72]. - The company is actively developing new products such as Palivizumab Injection for the treatment of influenza, which is classified as a chemical drug (Class 3) and is in the research phase[88]. Market Strategy and Sales - The company aims to establish itself as the leading brand in pediatric medicine in China, enhancing brand recognition through various health education initiatives[37]. - The company’s main sales channels include direct sales, traditional distribution, and e-commerce, covering a wide range of healthcare institutions[32]. - The company expanded its sales network, covering over 2,000 grade hospitals and 8,000 grassroots medical institutions by the end of 2020[44]. - The company has established a dedicated e-commerce department, forming strategic partnerships with major online platforms like JD.com and Taobao to enhance online sales channels[44]. Regulatory Compliance and Risks - The company faces risks from regulatory changes in the pharmaceutical industry, which could impact operations[111]. - Environmental protection regulations are becoming stricter, potentially increasing the company's compliance costs[112]. - The revised Drug Administration Law, effective from December 1, 2019, emphasizes risk management and comprehensive regulations for drug development, registration, and production, enhancing oversight and penalties for non-compliance[74]. Social Responsibility and Community Engagement - The company donated epidemic prevention clinical urgently needed medicines valued at 10.329 million yuan to the Hainan Red Cross Society[197]. - The company organized a rapid response to the COVID-19 pandemic, implementing emergency plans and coordinating the procurement of protective materials[197]. - The company received the "Special Contribution Award for COVID-19 Prevention and Control Work" from the Chinese Red Cross Society for its efforts during the pandemic[198]. Commitments and Governance - The company commits to ensuring that neither it nor its subsidiaries will engage in any competitive business activities with HuLuWa during the period of being a controlling shareholder and for six months thereafter[140]. - The company will strengthen the management of raised funds to ensure their proper use and compliance with regulatory requirements[154]. - The controlling shareholder has committed not to interfere in the company's management or infringe on its interests, with a willingness to compensate for any losses caused by such actions[150].

Financial Performance - Operating revenue decreased by 6.39% to CNY 813,140,630.47 for the first nine months compared to the same period last year[6] - Net profit attributable to shareholders increased by 58.55% to CNY 75,074,690.02 for the first nine months compared to the same period last year[6] - Basic and diluted earnings per share increased by 53.85% to CNY 0.20[7] - Total operating revenue for Q3 2020 was ¥237,587,471.47, a decrease of 7.5% compared to ¥257,876,611.60 in Q3 2019[28] - Net profit for Q3 2020 reached ¥32,561,221.96, significantly up from ¥6,706,183.98 in Q3 2019, representing a growth of 385.5%[30] - The company's operating revenue for the first three quarters of 2020 was CNY 583,096,310.02, a decrease of 3.5% compared to CNY 603,226,319.22 in the same period of 2019[32] - The net profit for the third quarter of 2020 was CNY 38,654,589.85, representing an 88.6% increase from CNY 20,514,529.23 in the third quarter of 2019[33] - The total operating profit for the first three quarters of 2020 was CNY 123,383,526.34, up 41.0% from CNY 87,539,397.94 in the first three quarters of 2019[33] Assets and Liabilities - Total assets increased by 27.77% to CNY 1,388,305,776.37 compared to the end of the previous year[6] - Current assets totaled CNY 862,294,331.76, up from CNY 546,273,014.16 in the previous year, indicating a year-over-year increase of about 57.7%[20] - Total liabilities amounted to CNY 518,255,766.54, compared to CNY 442,670,657.06 in the previous year, showing an increase of about 17%[21] - Total liabilities increased to ¥281,338,651.97 in Q3 2020 from ¥192,401,744.81 in Q3 2019, marking a rise of 46.2%[26] - The total assets of the company reached ¥1,179,702,914.95 in Q3 2020, up from ¥834,440,739.40 in Q3 2019, indicating a growth of 41.3%[26] - The total liabilities as of Q3 2020 amounted to ¥442,670,657.06, remaining stable compared to the previous year[42] Cash Flow - Net cash flow from operating activities decreased by 99.48% to -CNY 175,087,499.26 for the first nine months compared to the same period last year[6] - The cash flow from operating activities for the first three quarters of 2020 was negative CNY 175,087,499.26, compared to negative CNY 87,769,797.35 in the same period of 2019[36] - The total cash inflow from operating activities for the first three quarters of 2020 was CNY 673,577,454.69, down from CNY 778,815,914.67 in the same period of 2019[36] - The net cash flow from operating activities for the first three quarters of 2020 was -¥201,797,395.05, worsening from -¥84,112,931.67 in the same period of 2019[38] - The company reported a cash inflow from financing activities of ¥343,119,000.00 in Q3 2020, with a net cash flow of ¥283,214,030.16 after outflows[39] Shareholder Information - The total number of shareholders reached 29,809[12] - The top shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 41.76% of shares[12] - The company's equity attributable to shareholders rose to CNY 870,050,009.83 from CNY 643,935,667.58, representing an increase of approximately 35.2%[22] Government Support and Subsidies - The company received government subsidies amounting to CNY 32,516,597.88 during the reporting period[8] - The company reported a 614.41% increase in other income to RMB 32,516,597.88 from RMB 4,551,504.60, mainly due to increased government subsidies received during the first nine months of 2020[16] Operational Changes - The company has completed the construction of the warehouse in the Yao Valley plant, leading to a transfer of construction in progress to fixed assets[15] - The company is focusing on enhancing inventory management, resulting in a decrease in inventory impairment provisions[16] - The company has plans for market expansion and new product development, although specific figures and timelines were not disclosed in the report[20] Research and Development - Research and development expenses for Q3 2020 were ¥10,848,988.80, a decrease of 24.0% from ¥14,433,685.96 in Q3 2019[29] - Research and development expenses for the first three quarters of 2020 amounted to CNY 29,068,656.56, which is a 3.4% increase compared to CNY 28,110,910.81 in the same period of 2019[32]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥575,553,159, a decrease of 5.77% compared to ¥610,801,332.69 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥42,513,468.06, representing an increase of 4.60% from ¥40,644,240.56 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥38,079,991.76, up 7.23% from ¥35,511,024.62 year-on-year[18]. - Basic earnings per share for the reporting period increased by 9.09% to CNY 0.12 compared to CNY 0.11 in the same period last year[19]. - Diluted earnings per share also rose by 9.09% to CNY 0.12 from CNY 0.11 year-on-year[19]. - The company reported a net profit of -¥1,871.57 million for its subsidiary Hainan Huluwa, with revenue of ¥5,245.58 million[52]. - The total profit for the first half of 2020 was CNY 53,054,379.55, an increase of 1.7% from CNY 47,266,579.67 in the first half of 2019[185]. - The comprehensive income for the first half of 2020 was 42,513,468.06, compared to 40,644,240.56 in the same period of 2019, indicating an increase of about 4.6%[199]. Cash Flow and Assets - The net cash flow from operating activities was -¥153,676,574.65, a significant decline compared to -¥3,774,545.30 in the same period last year, reflecting a decrease of 3,971.39%[18]. - Cash and cash equivalents decreased by CNY 59.25 million, a reduction of 38.45%, primarily due to accounts receivable still within the credit period[29]. - Accounts receivable increased by CNY 175.80 million, an increase of 118.69%, mainly due to some accounts receivable still within the credit period[29]. - Total assets at the end of the reporting period reached ¥1,182,492,404.55, marking an increase of 8.82% from ¥1,086,606,324.64 at the end of the previous year[18]. - The company's cash and cash equivalents decreased to RMB 94,839,928.61 from RMB 154,089,300.78, a decline of approximately 38.4%[174]. - Total liabilities amounted to CNY 244,088,099.04, an increase of 27% from CNY 192,401,744.81 at the end of 2019[181]. Research and Development - The company increased R&D investment, focusing on pediatric, digestive, respiratory, anti-infection, anti-epileptic, and vitamin supplement treatments[39]. - Research and development expenses for the first half of 2020 were CNY 20,945,541.38, up 9.1% from CNY 19,194,812.54 in the same period of 2019[183]. Market and Competition - The company focuses on pediatric medications, with key products including respiratory and digestive system drugs[24]. - Increased competition in the pediatric medication market is anticipated due to growing demand and more companies entering the sector, potentially impacting market share[56]. Environmental Compliance - The company reported a total wastewater discharge limit of 2.289 million kg/year for CODCr, with no exceedance in the current reporting period[117]. - The company maintained compliance with air pollutant discharge standards, with nitrogen oxides emissions recorded at 2.43 mg/L, below the limit of 400 mg/L[119]. - The company has established a robust environmental compliance framework, ensuring adherence to all relevant pollution discharge standards[126]. - The company is committed to continuous improvement in environmental performance and sustainability practices[127]. Shareholder Commitments - The controlling shareholder, Huliwa Investment, committed not to transfer or manage shares for 36 months post-listing, with an automatic extension of the lock-up period if stock prices fall below the issue price for 20 consecutive trading days[66]. - If the stock price remains below the issue price for six months post-listing, the lock-up period for Huliwa Investment's shares will extend by an additional six months[66]. - The company will publicly apologize for any non-compliance with these commitments and will be liable for any losses incurred by investors[67][72]. Legal Matters - The company is involved in a significant lawsuit seeking the return of 1 million RMB and compensation totaling 1.7418 million RMB from Hainan Xinlai, with the case still pending judgment as of June 30, 2020[105]. - There are no significant litigation or arbitration matters reported for the current period, indicating a stable legal environment for the company[106]. Internal Management - The company is committed to improving internal management and operational quality through lean production and refined management practices[41]. - The accounting work is managed by Fu Qin, ensuring compliance and accuracy[200].